JP2014521700A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521700A5
JP2014521700A5 JP2014524151A JP2014524151A JP2014521700A5 JP 2014521700 A5 JP2014521700 A5 JP 2014521700A5 JP 2014524151 A JP2014524151 A JP 2014524151A JP 2014524151 A JP2014524151 A JP 2014524151A JP 2014521700 A5 JP2014521700 A5 JP 2014521700A5
Authority
JP
Japan
Prior art keywords
group
alkyl
halogen
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014524151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521700A (ja
JP6113727B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/049698 external-priority patent/WO2013022814A1/en
Publication of JP2014521700A publication Critical patent/JP2014521700A/ja
Publication of JP2014521700A5 publication Critical patent/JP2014521700A5/ja
Application granted granted Critical
Publication of JP6113727B2 publication Critical patent/JP6113727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014524151A 2011-08-05 2012-08-06 第xia因子阻害剤としての環状p1リンカー Active JP6113727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515404P 2011-08-05 2011-08-05
US61/515,404 2011-08-05
PCT/US2012/049698 WO2013022814A1 (en) 2011-08-05 2012-08-06 Cyclic p1 linkers as factor xia inhibitors

Publications (3)

Publication Number Publication Date
JP2014521700A JP2014521700A (ja) 2014-08-28
JP2014521700A5 true JP2014521700A5 (enExample) 2015-10-01
JP6113727B2 JP6113727B2 (ja) 2017-04-12

Family

ID=46964007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524151A Active JP6113727B2 (ja) 2011-08-05 2012-08-06 第xia因子阻害剤としての環状p1リンカー

Country Status (8)

Country Link
US (2) US8901115B2 (enExample)
EP (2) EP3070087B1 (enExample)
JP (1) JP6113727B2 (enExample)
CN (2) CN103702999B (enExample)
AR (1) AR088423A1 (enExample)
ES (2) ES2563445T3 (enExample)
TW (1) TW201319068A (enExample)
WO (1) WO2013022814A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5844287B2 (ja) 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのマクロ環
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
IN2014CN02806A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
IN2014CN02805A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
KR20150038372A (ko) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
CA2880898A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
NO2760821T3 (enExample) 2014-01-31 2018-03-10
JP6505727B2 (ja) * 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9663527B2 (en) 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3104702B1 (en) 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Factor xia inhibitors
WO2015164308A1 (en) 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
JP6526796B2 (ja) * 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Fxia阻害剤であるジアミドマクロ環
NO2721243T3 (enExample) 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
WO2016093285A1 (ja) * 2014-12-10 2016-06-16 小野薬品工業株式会社 ジヒドロインドリジノン誘導体
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
CN107849026B (zh) 2015-07-29 2021-01-01 百时美施贵宝公司 携带烷基或环烷基p2′部分的因子xia大环抑制剂
BR112018008506B8 (pt) 2015-10-29 2023-12-05 Merck Sharp & Dohme Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
CN109195973A (zh) 2016-03-02 2019-01-11 百时美施贵宝公司 具有因子xia抑制活性的二酰胺大环类化合物
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN110062757B (zh) * 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
WO2019011166A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 大环酰胺化合物及其药物组合物和用途
HUE062236T2 (hu) * 2018-04-17 2023-10-28 Univ Michigan Regents Vérlemezke funkció inhibitorok és eljárás azok alkalmazására
CN113677682B (zh) 2019-04-16 2023-05-30 华润生物医药有限公司 作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh) * 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
TW202515882A (zh) * 2023-06-30 2025-04-16 大陸商深圳信立泰藥業股份有限公司 一種多取代的大環化合物及其製備方法與應用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPH0987280A (ja) * 1995-09-28 1997-03-31 Yamanouchi Pharmaceut Co Ltd オキソピペラジン誘導体又はその塩
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
JP5225098B2 (ja) 2005-12-14 2013-07-03 ブリストル−マイヤーズ スクイブ カンパニー 第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
CN101389613B (zh) * 2005-12-23 2011-10-12 布里斯托尔-迈尔斯.斯奎布公司 用作抗凝血药的大环凝血因子viia抑制剂
TW200745062A (en) * 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
KR20100037600A (ko) 2007-06-13 2010-04-09 브리스톨-마이어스 스큅 컴퍼니 응고 인자 억제제로서의 디펩티드 유사체
EP2070899A1 (en) 2007-12-14 2009-06-17 F. Hoffmann-La Roche Ag Deprotection of N-BOC compounds
CN102026996B (zh) * 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
JP5844287B2 (ja) * 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのマクロ環
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
IN2014CN02805A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
IN2014CN02806A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
CA2880898A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
KR20150038372A (ko) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Similar Documents

Publication Publication Date Title
JP2014530240A5 (enExample)
JP2017504640A5 (enExample)
HRP20201927T1 (hr) PIRIMIDINONI KAO INHIBITORI FAKTORA XIa
JP2021088610A5 (enExample)
JP2014532070A5 (enExample)
JP2017504642A5 (enExample)
JP2014521701A5 (enExample)
RU2019107938A (ru) Производное оксопиколинамида, способ его получения и его фармацевтическое применение
JP2011520967A5 (enExample)
JP2017504641A5 (enExample)
IL298983B2 (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
JP2015524443A5 (enExample)
HRP20171122T1 (hr) Novi makrociklusi kao inhibitori faktora xia
JP2017525744A5 (enExample)
JP2019527215A5 (enExample)
HRP20172002T1 (hr) Makrociklički inhibitori faktora xia kondenzirani sa heterociklusima
JP2016517417A5 (enExample)
JP2018525371A5 (enExample)
JP2009536218A5 (enExample)
JP2013545818A5 (enExample)
JP2013545817A5 (enExample)
HRP20161378T1 (hr) Dihidropiridon kao faktor xia inhibitora
CA2749048A1 (en) Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases
JP2013544860A5 (enExample)
JP2016530259A5 (enExample)